Treatments used to control signs and symptoms in rosacea
DOI:
https://doi.org/10.33448/rsd-v10i2.12780Keywords:
Dermatology; Botulinum toxin type A; Rosacea; Anti-bacterial agents; Adrenal cortex hormones.Abstract
A rosácea é uma patologia inflamatória crônica, que atua de forma progressiva, ou seja, o quadro clínico tende a se agravar com o passar do tempo e com ausência do devido controle terapêutico. Pode ser considerada uma síndrome. Sua etiopatogenia tem como base questões multifatoriais, sendo desencadeada por diversos mecanismos. A rosácea ainda não possui um tratamento curativo e as terapias disponíveis, como antibióticos, corticoides e alguns procedimentos alternativos, atuam no controle dos sinais e sintomas, melhorando as manifestações clínicas. Assim, o objetivo deste trabalho foi analisar, por meio de um levantamento bibliográfico, os tratamentos existentes para os sinais e sintomas da rosácea, bem como os possíveis prejuízos que alguns tratamentos podem causar ao organismo dos indivíduos por ela acometidos. Para fundamentar o presente artigo, foram selecionados 39 artigos, datados de 2004 a 2019 nas bases de dados Surgical and Cosmetic Dermatology, Lilacs, PubMed, Scielo e Google acadêmico. Observou-se que os tratamentos mais tradicionais, como o uso de antibióticos, corticoides e vasoconstritor, podem causar danos ao organismo de forma sistêmica, a exemplo de lesões hepáticas, eventos no trato gastrointestinal e agravamento no quadro de insuficiência vascular. Desta forma os tratamentos alternativos, entre os quais a aplicação toxina botulínica do tipo A possuem um futuro promissor, pois promovem uma resposta satisfatória e com índice de efeitos colaterais muito baixos em comparação aos tratamentos já utilizados.
References
Abram, K., Silm, H., Maaroos, H. I., & Oona, M. (2010). Risk factors associated with rosacea. Journal of the European Academy of Dermatology and Venereology, 24(5), 565-571.
Antonio, C. R., Antonio, J. R., Trídico, L. A., & Fernandes, T. É. A. (2017). Tratamento de Rosácea com Toxina Botulínica. Surgical & Cosmetic Dermatology, 10(3), 36-39.
Augustin, M., Herberger, K., Hintzen, S., Heigel, H., Franzke, N., & Schäfer, I. (2011). Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. British Journal of Dermatology, 165(4), 865-873.
Awosika, O., & Oussedik, E. (2018). Genetic predisposition to rosacea. Dermatologic Clinics, 36(2), 87-92.
Bloom, B. S., Payongayong, L., Mourin, A., & Goldberg, D. J. (2015). Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatologic Surgery, 41, S9-S16.
Buhl, T., Sulk, M., Nowak, P., Buddenkotte, J., McDonald, I., Aubert, J., & Voegel, J. J. (2015). Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. Journal of Investigative Dermatology, 135(9), 2198-2208.
Choi, J. E., Werbel, T., Wang, Z., Wu, C. C., Yaksh, T. L., & Di Nardo, A. (2019). Botulinum toxin blocks mast cells and prevents rosacea like inflammation. Journal of Dermatological Science, 93(1), 58-64.
Couto, L., Ferreira, I. L. O., da Silveira, M. L., & Steiner, D. (2018). Estudo prospectivo para tratamento do rubor da rosácea com toxina botulínica tipo A. Surgical & Cosmetic Dermatology, 10(2), 121-126.
Chamusca, F. V., Reis, S. R. A., Lemaire, D., & Medrado, A. P. (2012). Mediadores do efeito sistêmico do processo inflamatório e terapias fotobiomoduladoras: uma revisão de literatura. Revista de Ciências Médicas e Biológicas, 11(1), 70-78
Chen, S. (2012). Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins, 4(10), 913-939.
Crawford, G. H., Pelle, M. T., & James, W. D. (2004). Rosacea: I. Etiology, pathogenesis, and subtype classification. Journal of the American Academy of Dermatology, 51(3), 327-341.
Cribier, B. (2013). Rosacea under the microscope: characteristic histological findings. Journal of the European Academy of Dermatology and Venereology, 27(11), 1336-1343.
Dayan, S. H., Pritzker, R. N., & Arkins, J. P. (2012). A new treatment regimen for rosacea: onabotulinumtoxinA. Journal of Drugs in Dermatology, 11(12), e76-e79.
Del Rosso, J. Q. (2012). Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. The Journal of Clinical and Aesthetic Dermatology, 5(3), 16-25.
Di Matteo, M. C., Stefano, P. C., Cirio, A., López, B., Centeno, M., Bocian, M., & Cervini, A. B. (2019). Rosácea oculocutánea en un niño. Arquivos Argentinos de Pediatria, 170-172.
Draelos, Z. D., Elewski, B., Staedtler, G., & Havlickova, B. (2013). Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis, 92(6), 306-317.
Duman, N., Ersoy Evans, S., & Atakan, N. (2014). Rosacea and cardiovascular risk factors: a case control study. Journal of the European Academy of Dermatology and Venereology: JEADV, 28(9), 1165–1169.
Feldman, S. R., Huang, W. W., & Huynh, T. T. (2014). Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease. Journal of Managed Care Pharmacy, 20(6), 623-629.
Fowler Jr, J., Jackson, M., Moore, A., Jarratt, M., Jones, T., Meadows, K., & Leoni, M. (2013). Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. Journal of Drugs in Dermatology: JDD, 12(6), 650-656.
Kim, J. Y., Kim, Y. J., Lim, B. J., Sohn, H. J., Shin, D., & Oh, S. H. (2014). Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea. Yonsei Medical Journal, 55(6), 1648-1655.
Korting, H. C., & Schöllmann, C. (2009). Current topical and systemic approaches to treatment of rosacea. Journal of the European Academy of Dermatology and Venereology, 23(8), 876-882.
Lanoue, J., & Goldenberg, G. (2015). Therapies to improve the cosmetic symptoms of rosacea. Cutis, 96(1), 19-26.
Marques, R. Z. S., Moran, D. K. S., Speyer, C., Azevedo, L. C. M., & Cohen, S. (2016). Tratamento de rosácea com duas faixas de comprimento de onda de luz intensa pulsada num mesmo disparo. Surgical & Cosmetic Dermatology, 8(2), 128-132.
Melnik, B. C. (2016). Rosacea: the blessing of the Celts–an approach to pathogenesis through translational research. Acta Dermato-Venereologica, 96(2), 147-156.
Moore, A., Kempers, S., Murakawa, G., Weiss, J., Tauscher, A., Swinyer, L., & Leoni, M. (2014). Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. Journal of Drugs in Dermatology: JDD, 13(1), 56-61.
Moustafa, F., Hopkinson, D., Huang, K. E., & Feldman, S. (2015). Prevalence of rosacea in community settings. Journal of Cutaneous Medicine and Surgery, 19(2), 149-152.
Okhovat, J. P., & Armstrong, A. W. (2014). Updates in rosacea: epidemiology, risk factors, and management strategies. Current Dermatology Reports, 3(1), 23-28.
Park, K. Y., Hyun, M. Y., Jeong, S. Y., Kim, B. J., Kim, M. N., & Hong, C. K. (2015). Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology, 230(4), 299-301.
Pereira A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB / NTE / UFSM. Retrieved from: https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1.
Reinholz, M., Ruzicka, T., & Schauber, J. (2012). Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Annals of dermatology, 24(2), 126-135.
Schaller, M., Almeida, L. M. C., Bewley, A., Cribier, B., Dlova, N. C., Kautz, G., ... & Thiboutot, D. (2017). Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. British Journal of Dermatology, 176(2), 465-471.
Steinhoff, M., Schauber, J., & Leyden, J. J. (2013). New insights into rosacea pathophysiology: a review of recent findings. Journal of the American Academy of Dermatology, 69(6), S15-S26.
Steinhoff, M., Schmelz, M., & Schauber, J. (2016). Facial erythema of rosacea-aetiology, different pathophysiologies and treatment options. Acta dermato-venereologica, 96(5), 579-589.
Tan, J., & Berg, M. (2013). Rosacea: current state of epidemiology. Journal of the American Academy of Dermatology, 69(6), S27-S35.
Trindade Neto, P. B. D., Rocha, K. B. F., Lima, J. B. D., Nunes, J. C. S., & Silva, A. C. D. O. (2006). Rosácea granulomatosa: relato de caso-enfoque terapêutico. Anais Brasileiros de Dermatologia, 81, S320-S323.
Two, A. M., & Del Rosso, J. Q. (2014). Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. The Journal of Clinical and Aesthetic Dermatology, 7(1), 20-25.
Two, A. M., Wu, W., Gallo, R. L., & Hata, T. R. (2015a). Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. Journal of the American Academy of Dermatology, 72(5), 749-758.
Two, A. M., Wu, W., Gallo, R. L., & Hata, T. R. (2015b). Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. Journal of the American Academy of Dermatology, 72(5), 761-770.
Weinkle, A. P., Doktor, V., & Emer, J. (2015). Update on the management of rosacea. Clinical, Cosmetic and Investigational Dermatology, 8, 159-177.
Wilkin, J., Dahl, M., Detmar, M., Drake, L., Liang, M. H., Odom, R., & Powell, F. (2004). Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. Journal of the American Academy of Dermatology, 50(6), 907-912.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Karla Glazielle Gonçalves dos Santos Malachoski ; João Luiz Coelho Ribas
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
